Most recent notes from BoA, "KALA provided updates on the preclinical programs, such as tyrosine kinase inhibitor program in retinal diseases (e.g. wet AMD), selective glucocorticoid receptor modulators (SEGRMs) and novel steroids. Mgmt. believes there is high unmet need in areas, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME) which require frequent administration and lead to poor compliance as a consequence.
1) the company continues to view payor access as an important factor in the success of the ongoing Eysuvis launch and is planning to provide updates on coverage on quarterly earnings calls. Management noted Eysuvis use will likely follow the payor mix of the DED market, which 50% of total Rx volume is currently commercial, 40% Medicare and the remaining 10% with a mix of cash and Medicaid. On out of pocket cost, copay is expected to be in the $25-$45 range at preferred tier and $50-$70 if not preferred. The company also has copay assistance cards in place to ease the potential hurdles to access with max. out of pocket cost of $40, and 2) its sales force of 91 reps is now in place with plans to expand to ~125 reps in 2021 pending visibility on COVID. Noting 80%+ of sales calls are in person, KALA is planning to ramp up its peer-to-peer programs in both virtual and live format. Recall our surveys of ophthalmologists (handling ~55% DED prescription) and optometrists (~45%) indicated the unmet need and demand for a short term DED relief option like Eysuvis.
1) the company continues to view payor access as an important factor in the success of the ongoing Eysuvis launch and is planning to provide updates on coverage on quarterly earnings calls. Management noted Eysuvis use will likely follow the payor mix of the DED market, which 50% of total Rx volume is currently commercial, 40% Medicare and the remaining 10% with a mix of cash and Medicaid. On out of pocket cost, copay is expected to be in the $25-$45 range at preferred tier and $50-$70 if not preferred. The company also has copay assistance cards in place to ease the potential hurdles to access with max. out of pocket cost of $40, and 2) its sales force of 91 reps is now in place with plans to expand to ~125 reps in 2021 pending visibility on COVID. Noting 80%+ of sales calls are in person, KALA is planning to ramp up its peer-to-peer programs in both virtual and live format. Recall our surveys of ophthalmologists (handling ~55% DED prescription) and optometrists (~45%) indicated the unmet need and demand for a short term DED relief option like Eysuvis.
